Articles tagged "Rejection"

2016 American Transplant Congress
First Clinical Experience with Belatacept in 3 Hand Transplanted Patients.
J. Grahammer,¹ B. Zelger,² B. Zelger,³ M. Ninkovic,¹ A. Muehlbacher,⁴ D. Oefner-Velano,¹ S. Schneeberger,¹ A. Weissenbacher.⁵
¹Viceral, Thoracic and Transplant Surgery, Innsbruck Medical University, Innsbruck, Austria; ²Dermatology and Venerology, Innsbruck Medical University, Innsbruck, Austria; ³Pathology, Innsbruck Medical University, Innsbruck, Austria; ⁴Department of Blood Group Serology and Transfusion Medicine, Innsbruck Medical University, Innsbruck, Austria; ⁵Oxford Transplant Centre, Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom.
Study purposeBelatacept (CTLA4Ig) is an emerging treatment in solid organ transplantation. Effects on the development of donor specific antibodies (DSA) as well as its clinical…
2016 American Transplant Congress
DEPTOR Inhibits mTORC1 in CD4⁺ T Cells and Increases Treg Function by Stabilizing Foxp3 Expression.
J. Wedel,^1,2 S. Bruneau,^1,2 D. Briscoe.^1,2
¹Division of Nephrology, Boston Children's Hospital, Boston, MA; ²Transplant Research Program, Harvard Medical School, Boston, MA.
The modulation of PI-3K/Akt-induced signaling is critical for CD4+ Treg homeostasis and stability. Moreover, activation of PI-3K/Akt/mTOR signals within T cell subsets is associated with…
2016 American Transplant Congress
The Impact of Ritonavir-Boosted Protease Inhibitors and Non-Depleting Antibody Induction on Outcomes in HIV-Infected Kidney Transplant Recipients.
B. Rollins, S. Lerner, M. Rana, S. Huprikar, L. Miko, V. Nair, S. Florman, R. Shapiro.
Mount Sinai Hospital, New York.
Background: One-year rejection rates in HIV-infected kidney transplant recipients range from 15-40%, compared to overall rejection rates of 10% in HIV-negative patients. Protocols for immunosuppression…
2016 American Transplant Congress
Phenotype and Outcome of Antibody-Mediated Rejection Due to Pre-Existing and De Novo DSA in Kidney Recipients.
O. Aubert,¹ A. Loupy,¹ L. Hidalgo,² J. Reeve,³ D. Glotz,¹ C. Legendre,¹ C. Lefaucheur,¹ P. Halloran.³
¹Paris Research Center for Organ Transplantation, Paris, France; ²University of Alberta, Edmonton, Canada; ³ATAGC, Edmonton, Canada.
Antibody-mediated rejection (ABMR) presents with either pre-existing or de novo DSA. The aim of the study was to compare the two ABMR phenotypes and their…
2016 American Transplant Congress
Rapid Detection of Urinary CXCL9 as a Diagnostic and Prognostic Tool for Managing Acute Cellular Rejection (ACR) in Kidney Transplantation.
I. Gandolfini,¹ C. Harris,¹ C. Purroy,¹ V. Nair,¹ J. Reid-Adam,¹ O. Bestard,² P. Heeger.¹
¹Icahn School of Medicine at Mount Sinai, New York, NY; ²Bellvitge University Hospital, Barcelona, Spain.
Urinary (u) CXCL9 protein expression can noninvasively diagnose ACR and serial measurements during CNI withdrawal indicate that elevations in uCXCL9 detect subclinical rejection. How elevated…
2016 American Transplant Congress
Outcomes with Steroids Alone for Biopsy-Proven Pancreas Transplant Rejection.
S. Salahuddin,¹ B. Astor,¹ S. Parajuli,¹ A. Djamali,¹ J. Odorico,² D. Mandelbrot.¹
¹Department of Nephrology, University of Wisconsin, Madison, WI; ²Department of Surgery, University of Wisconsin, Madison, WI.
There is little published data on the response of pancreas rejection to steroids alone. We reviewed 42 pancreas transplant recipients between 01/1997 and 12/2013 at…
2016 American Transplant Congress
Continuous Antithymocyte Globulin (rATG) for Treatment of Renal Allograft Rejection: Preliminary Analysis of a Prospective, Randomized Trial.
S. Patel, R. Knight, S. Kuten, J. Nolte, A. Gaber.
Houston Methodist Hospital, Houston, TX.
Intravenous (IV) rATG for acute rejection (AR) is primarily given on an inpatient basis due to its daily administration, IV access requirement, and monitoring. The…
2016 American Transplant Congress
CD45RO+/CD62L- Effector Memory T Cells Mediate Depletion Resistant Allograft Rejection in Intestinal Transplant Recipients.
C. Cosentino, J. Kaiser, A. Shukla, C. Desai, R. Girlanda, J. Hawksworth, C. Matsumoto, M. Zasloff, T. Fishbein, A. Kroemer.
MedStar Georgetown Transplant Institute, Washington DC.
A. A high risk of acute cellular rejection (ACR) is one of the key factors limiting intestinal transplantation (ITx). An extremely poor prognosis is related…
2016 American Transplant Congress
Frequency and Utility of Donor-Specific Antibody Testing in Simultaneous Liver Kidney Transplant.
A. Morrison,¹ D. Sawinski,² M. Kamoun,³ P. Porrett.¹
¹Surgery, University of Pennsylvania, Philadelphia, PA; ²Medicine, University of Pennsylvania, Philadelphia, PA; ³Pathology, University of Pennsylvania, Philadelphia, PA.
Introduction: The risk of antibody mediated rejection (AMR) in simultaneous liver kidney (SLK) recipients is thought to be lower than in kidney alone patients due…
2016 American Transplant Congress
Antibody Titers as Predictors of Kidney Graft Outcomes.
A. Gilbert,¹ M. Zaheer,¹ O. Timofeeva,² S. Rosen-Bronson,² M. Awwad,² D. Li,² M. Grafals,¹ B. Javaid,¹ P. Abrams,¹ J. Verbesey,¹ M. Cooper.¹
¹Surgery, MedStar Georgetown Transplant Institute, Washington, DC; ²Pathology, MedStar Georgetown Transplant Institute, Washington, DC.
PURPOSE: Development of de novo donor specific antibody (dnDSA) following kidney transplantation is not uncommon. As laboratory techniques advance, rates of dnDSA have increased. However,…